GlassScriptPhysician profile
Anne Loretta Hall
NPI 1194457937
$2,815.65
in general payments reported to CMS, 2019-2025
34 companies · $757 in 2025
The $757 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $87.52 · 2023: $917 · 2024: $1,054 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,728.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $634.75 | 2023-2025 | |
| Pfizer INC. | $374.90 | 2023-2025 | |
| Novo Nordisk INC | $165.84 | 2023-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $136.37 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $118.22 | 2022-2024 | |
| Amgen INC. | $110.29 | 2023-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $105.67 | 2023-2025 | Mounjaro, Kisunla, Zepbound |
| Otsuka America Pharmaceutical, INC. | $100.86 | 2023-2024 | Rexulti, Nuedexta |
| Alexion Pharmaceuticals, INC. | $82.90 | 2023-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.82 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.90 | 2022-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $68.06 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sumitomo Pharma America, INC. | $56.84 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $55.41 | 2023-2025 | |
| Harmony Biosciences LLC | $53.41 | 2023-2024 | Wakix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $53.09 | 2023 | Tymlos |
| Janssen Pharmaceuticals, INC | $52.64 | 2024 | Spravato, Xarelto |
| Sanofi-Aventis U.S. LLC | $52.46 | 2024 | |
| Exact Sciences Corporation | $52.26 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $49.25 | 2023 | Quviviq |
| Nevro Corp. | $40.32 | 2022-2023 | Senza |
| Axsome Therapeutics, INC. | $39.76 | 2023-2024 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $35.46 | 2024-2025 | Trintellix |
| Glaxosmithkline, LLC. | $31.69 | 2025 | Arexvy, Shingrix |
| Lundbeck LLC | $24.49 | 2023 | Rexulti |
| Abbott Laboratories | $24.02 | 2024 | Freestyle Libre 3 |
| Phadia US INC. | $23.69 | 2025 | Immunocap |
| Edwards Lifesciences Corporation | $22.40 | 2025 | Sapien 3 Ultra Resilia |
| Ibsa Pharma INC. | $19.64 | 2025 | Tirosint, Licart, Flector |
| Abiomed | $19.02 | 2025 | |
| Daiichi Sankyo INC. | $17.52 | 2024 | Injectafer |
| Boston Scientific Corporation | $17.35 | 2024 | Wavewriter Alpha Prime 16 |
| Teva Pharmaceuticals USA, INC. | $14.52 | 2023 | Airduo Digihaler |
| Tactile Systems Technology INC | $12.83 | 2023 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.